Abstract
In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Current Drug Discovery Technologies
Title:Network Pharmacology: Reigning in Drug Attrition?
Volume: 10 Issue: 2
Author(s): Osama M. Alian, Minjel Shah, Momin Mohammad and Ramzi M. Mohammad
Affiliation:
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Abstract: In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Export Options
About this article
Cite this article as:
M. Alian Osama, Shah Minjel, Mohammad Momin and M. Mohammad Ramzi, Network Pharmacology: Reigning in Drug Attrition?, Current Drug Discovery Technologies 2013; 10 (2) . https://dx.doi.org/10.2174/1570163811310020008
DOI https://dx.doi.org/10.2174/1570163811310020008 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety Role of P-glycoprotein in the Transport of Tanshinone I, One Active Triterpenoid from Salvia miltiorrhiza
Drug Metabolism Letters Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins
Current Protein & Peptide Science Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry SNP Analysis Combined with Protein Structure Prediction Defines Structure- Functional Relationships in Cancer Related Cytochrome P450 Estrogen Metabolism
Current Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi
Current Medicinal Chemistry Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Glucosinolates – Secondary Plant Products as Important Complex Interaction in our Biosphere
Current Nutrition & Food Science Combined Effect of Vaccinium nilgiriensis Bark Extract and 680nm Laser Irradiation in Inducing Breast Cancer Cell Death
Anti-Cancer Agents in Medicinal Chemistry